View More Recent Stories
-
Guardant Health (GH) Tops Q2 EPS by 26c ; Offers Guidance
-
Guardant Health's (GH) FDA-approved Shield Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer
-
Guardant Health (GH) PT Raised to $50 at BTIG, 'one of our top two picks in 2024'
-
Exact Sciences (EXAS) Slips 5% After Rival Colorectal Cancer Test Approved by FDA
-
Guardant Health's (GH) Shield Blood Test Approved by FDA as Primary Screening Option, Clearing Path for Medicare Reimbursement
-
Guardant Health (GH) Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360 Test
-
Guardant Health (GH) Appoints Manuel Hidalgo Medina to its Board
